Ratings AbbVie Inc. NEO Exchange

Equities

ABBV

CA00288K1084

End-of-day quote NEO Exchange Other stock markets 06:00:00 2024-07-10 pm EDT			5-day change	1st Jan Change
24.65 ^CAD	+0.94%		+1.44%	+8.73%

Jul. 11	Morgan Stanley Adjusts Price Target on AbbVie to $196 From $191	MT
Jul. 10	Redburn Atlantic Adjusts Price Target on AbbVie to $203 From $207	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

The earnings growth currently anticipated by analysts for the coming years is particularly strong.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
The opinion of analysts covering the stock has improved over the past four months.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

The company is in debt and has limited leeway for investment
With an expected P/E ratio at 29.21 and 24.05 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
The company's "enterprise value to sales" ratio is among the highest in the world.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the past year, analysts have significantly revised downwards their profit estimates.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
ABBVIE INC.	+8.73%	297B	-
ELI LILLY AND COMPANY	+60.25%	846B	C+
NOVO NORDISK A/S	+38.56%	628B	B
JOHNSON & JOHNSON	-4.49%	360B	C+
MERCK & CO., INC.	+18.30%	322B	B-
ASTRAZENECA PLC	+14.15%	240B	B+
ROCHE HOLDING AG	+3.11%	224B	A+
NOVARTIS AG	+16.98%	223B	B-
AMGEN INC.	+12.87%	173B	C+
PFIZER, INC.	-0.45%	161B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes